William Blair Has Optimistic Outlook of KROS FY2025 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Equities research analysts at William Blair lifted their FY2025 earnings per share estimates for Keros Therapeutics in a research note issued to investors on Wednesday, November 5th. William Blair analyst M. Phipps now forecasts that the company will post earnings of $2.23 per share for the year, up from their previous estimate of $0.82. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. William Blair also issued estimates for Keros Therapeutics’ Q4 2025 earnings at ($0.48) EPS, Q1 2026 earnings at ($0.65) EPS, Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($2.84) EPS, FY2027 earnings at ($2.72) EPS and FY2028 earnings at ($2.44) EPS.

A number of other equities analysts also recently issued reports on the stock. Wells Fargo & Company decreased their price target on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday. Weiss Ratings reissued a “sell (d)” rating on shares of Keros Therapeutics in a research report on Wednesday, October 8th. Zacks Research upgraded Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. HC Wainwright reduced their price target on Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Wedbush raised their price objective on Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $29.78.

Keros Therapeutics Trading Down 0.8%

Shares of KROS opened at $16.90 on Monday. The firm’s 50-day moving average price is $15.56 and its 200-day moving average price is $14.67. The firm has a market capitalization of $514.94 million, a price-to-earnings ratio of 10.97, a PEG ratio of 0.38 and a beta of 1.12. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.93. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The business had revenue of $14.26 million for the quarter, compared to the consensus estimate of $4.22 million. During the same period in the previous year, the firm earned ($1.41) EPS. The company’s quarterly revenue was up 3585.6% compared to the same quarter last year.

Insider Activity at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $95,659,436.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $84,975,125.25. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors have recently modified their holdings of the business. CWM LLC increased its holdings in Keros Therapeutics by 10,157.7% in the 1st quarter. CWM LLC now owns 2,667 shares of the company’s stock worth $27,000 after buying an additional 2,641 shares in the last quarter. Corton Capital Inc. purchased a new stake in shares of Keros Therapeutics during the 1st quarter valued at about $186,000. Federated Hermes Inc. grew its stake in shares of Keros Therapeutics by 882.3% in the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock worth $12,474,000 after acquiring an additional 1,099,519 shares during the period. XTX Topco Ltd purchased a new position in shares of Keros Therapeutics during the first quarter valued at approximately $490,000. Finally, Vanguard Group Inc. raised its holdings in shares of Keros Therapeutics by 31.1% during the first quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company’s stock valued at $26,151,000 after purchasing an additional 609,212 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.